세계의 생체내 프라임 에디팅 플랫폼 시장 보고서(2025년)
In-vivo Prime Editing Platform Global Market Report 2025
상품코드 : 1855908
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ₩ 6,666,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ₩ 9,635,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ₩ 12,605,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

생체내 프라임 에디팅 플랫폼 시장 규모는 최근 급격히 확대되고 있습니다. 2024년 9억 7,000만 달러에서 2025년에는 12억 6,000만 달러에 달하고, CAGR 29.5%로 성장할 전망입니다. 실적기간 내 성장은 임상적 응용 증가, 건강 관리 지출 증가, 유전성 질환의 유병률 증가, 프라임 에디팅 기술의 채용 확대, 유전체 연구에 대한 투자 증가에 의해 발생하였습니다.

생체내 프라임 에디팅 플랫폼 시장 규모는 향후 수년간 비약적인 성장이 예상됩니다. 2029년에는 CAGR 29.2%로 35억 달러로 성장할 전망입니다. 예측기간 내 성장은 맞춤 의료에 대한 수요 증가, 유전성 질환과 암의 유병률 증가, 민간 및 정부로부터의 자금 제공의 확대, 환자의 의식 향상, 유전자 편집 요법의 폭넓은 채용에 의해 지지되고 있습니다. 이 기간의 주요 동향에는 전달 시스템 개발, 가이드 RNA 설계 혁신, 인공지능 및 머신러닝 통합, 지질 나노입자(LNP) 플랫폼 개발, 전략적 공동 연구 및 파트너십 성장 등이 있습니다.

정확하고 효율적인 유전자 편집 솔루션에 대한 수요 증가는 생체내 프라임 에디팅 플랫폼 시장의 확대를 촉진할 것으로 예측됩니다. 유전자 편집은 의도하지 않은 편집과 잠재적인 부작용을 최소화하면서 유전 정보를 전달하는 분자인 DNA를 정확하게 변경하는 것을 말합니다. 이 수요는 오류를 줄이고 지속적인 임상 효과를 제공하는 표적 치료에 대한 요구가 증가함에 따라 크게 뒷받침됩니다. 생체내 프라임 에디팅 플랫폼은 생체 조직 내에서 정밀한 표적 DNA 수정을 가능하게 함으로써 이러한 요구에 대응하여, 표적 외 조직에 대한 영향을 최소화하고 장기적인 치료 효과를 기대할 수 있습니다. 예를 들어, 세계 경제 포럼은 전 세계적으로 2,000가지 이상의 유전자 치료가 개발 중이며, 그 수는 3년 전에 비해 두 배나 증가했다고 보고했습니다. 따라서, 정확하고 효율적인 유전자 편집 솔루션에 대한 수요 증가가 생체내 프라임 에디팅 플랫폼 시장의 성장에 기여하고 있습니다.

생체내 프라임 에디팅 플랫폼 시장의 각 회사는 생체내 치료의 표적화와 접근성을 향상시키기 위해 전달 시스템의 혁신에 주력하고 있습니다. 지질 나노입자, 바이러스 벡터, 인공 세포 외 소포와 같은 고급 전달 방법은 Cas9 니카제, 역전사 효소, pegRNA와 같은 프라임 에디팅 구성 요소를 캡슐화하는 데 매우 중요합니다. 이러한 캐리어는 편집 도구를 분해로부터 보호하여, 표적 세포로의 효율적인 전달을 촉진하고, 조직 특이성을 향상시킵니다. 예를 들어, 2023년 9월 미국의 생명공학 회사인 Moderna는 최적화된 지질 나노입자 제형을 통해 동물 모델 간 및 근육 조직에 고정밀도로 편집 도구를 전달할 수 있음을 입증했습니다. 이를 통해 표적 외 조직에 대한 영향을 최소화하면서 표적을 좁힌 유전체 변경이 가능해져 전달 시스템의 혁신이 생체내 프라임 에디팅 기술의 정확성과 치료 가능성을 어떻게 높이고 있는지를 보여줍니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

CSM
영문 목차

영문목차

The in-vivo prime editing platform is an advanced genome editing technology that allows precise, targeted DNA modifications directly within living organisms. It integrates a catalytically impaired CRISPR-Cas enzyme with a reverse transcriptase and employs a prime editing guide RNA (pegRNA) to introduce specific base changes, insertions, or deletions without causing double-strand breaks. This technique enables accurate correction of genetic mutations in tissues or organs, holding significant promise for therapeutic applications, particularly for inherited genetic disorders.

The primary product categories in the in-vivo prime editing platform include prime editing enzymes, guide RNAs (gRNAs), delivery systems, and related products. Prime editing enzymes are engineered proteins formed by fusing CRISPR-associated protein 9 nickase (Cas9 H840A) with reverse transcriptase (RT), typically derived from Moloney murine leukemia virus reverse transcriptase (M-MLV RT). In this system, the Cas9 nickase introduces a single-strand break in DNA, while the reverse transcriptase uses an RNA template to directly implement the intended modification. This allows precise search-and-replace genome editing without double-strand breaks, enhancing both safety and efficiency. Demand for prime editing enzymes is increasing alongside the advancement of clinical gene editing.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The fast surge in U.S. tariffs and the trade tensions that followed in spring 2025 are heavily affecting the medical equipment sector, particularly for imported imaging machine components, surgical-grade stainless steel, and plastic disposables. Hospitals and clinics resist price hikes, pressuring manufacturers' margins. Regulatory hurdles compound the problem, as tariff-related supplier changes often require re-certification of devices, delaying time-to-market. Companies are mitigating risks by dual-sourcing critical parts, expanding domestic production of commoditized items, and accelerating R&D in cost-efficient materials.

The in-vivo prime editing platform market research report is one of a series of new reports from The Business Research Company that provides in-vivo prime editing platform market statistics, including in-vivo prime editing platform industry global market size, regional shares, competitors with the gene circuit therapeutics market share, in-vivo prime editing platform market segments, market trends, and opportunities, and any further data you may need to thrive in the in-vivo prime editing platform industry. This in-vivo prime editing platform market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The in-vivo prime editing platform market size has grown exponentially in recent years. It will grow from $0.97 billion in 2024 to $1.26 billion in 2025 at a compound annual growth rate (CAGR) of 29.5%. The growth during the historic period is driven by increasing clinical applications, rising healthcare expenditures, growing prevalence of genetic diseases, expanding adoption of prime editing technologies, and higher investments in genomic research.

The in-vivo prime editing platform market size is expected to see exponential growth in the next few years. It will grow to $3.50 billion in 2029 at a compound annual growth rate (CAGR) of 29.2%. The projected growth in the forecast period is supported by rising demand for personalized medicine, increasing prevalence of hereditary diseases and cancer, greater funding from public and private sectors, higher patient awareness, and broader adoption of gene editing therapies. Key trends in this period include advancements in delivery systems, innovations in guide RNA design, integration of artificial intelligence and machine learning, development of lipid nanoparticle (LNP) platforms, and growth in strategic collaborations and partnerships.

The growing demand for precise and efficient genome-editing solutions is expected to drive the expansion of the in-vivo prime editing platform market. Genome editing involves making accurate, targeted changes to DNA-the molecule that carries genetic information-while minimizing unintended edits and potential side effects. This demand is largely driven by the increasing need for targeted therapies that reduce errors and provide lasting clinical benefits. In-vivo prime editing platforms address this need by enabling highly accurate, targeted DNA corrections within living tissues, with minimal off-target effects and the potential for long-term therapeutic benefits. For instance, the World Economic Forum reported that over 2,000 gene therapies were in development worldwide, double the number from just three years ago. As a result, the rising demand for precise and efficient genome-editing solutions is contributing to the growth of the in-vivo prime editing platform market.

Companies in the in-vivo prime editing platform market are focusing on innovations in delivery systems to improve the targeting and accessibility of in-vivo therapies. Advanced delivery methods, such as lipid nanoparticles, viral vectors, and engineered extracellular vesicles, are crucial for encapsulating prime editing components such as Cas9 nickase, reverse transcriptase, and pegRNAs. These carriers protect the editing tools from degradation, facilitate efficient delivery into target cells, and improve tissue specificity. For example, in September 2023, Moderna, a US-based biotechnology company, demonstrated that optimized lipid nanoparticle formulations could deliver prime editing machinery to liver and muscle tissues in animal models with high precision. This allowed targeted genome modifications while minimizing off-target effects, showcasing how innovations in delivery systems are enhancing the precision and therapeutic potential of in-vivo prime editing therapies.

In July 2025, Eli Lilly and Company, a US-based pharmaceutical firm, acquired Verve Therapeutics, Inc. for an undisclosed sum. This acquisition aims to revolutionize the treatment of cardiovascular disease by developing one-time genetic therapies that provide lifelong cardiovascular risk reduction. Verve Therapeutics is a clinical-stage biotechnology company focused on using gene-editing technologies to develop genetic medicines for cardiovascular conditions.

Major players in the in-vivo prime editing platform market are AstraZeneca PLC, Danaher Corporation, Regeneron Pharmaceuticals Inc., Moderna Inc., Integrated DNA Technologies Inc., Beam Therapeutics Inc., CRISPR Therapeutics AG, Maravai LifeSciences Holdings Inc., Sangamo Therapeutics Inc., Editas Medicine Inc., Precision BioSciences Inc., Metagenomi Inc., Tessera Therapeutics Inc., Mammoth Biosciences Inc., Arbor Biotechnologies Inc., Intellia Therapeutics Inc. (NTLA), Caribou Biosciences Inc., Scribe Therapeutics Inc., EGENESIS INC., Prime Medicine Inc., Cellectis S.A.

North America was the largest region in the in-vivo prime editing platform market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in in-vivo prime editing platform report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the in-vivo prime editing platform market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The in-vivo prime editing platform market consists of revenues earned by entities by providing services such as gene sequencing, genetic analysis, CRISPR -based editing, therapeutic development, preclinical testing. The market value includes the value of related goods sold by the service provider or included within the service offering. The in-vivo prime editing platform market also includes sales of gene editing kits, reagents, enzymes, plasmids, delivery vectors. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

In-vivo Prime Editing Platform Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on in-vivo prime editing platform market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for in-vivo prime editing platform ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The in-vivo prime editing platform market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. In-vivo Prime Editing Platform Market Characteristics

3. In-vivo Prime Editing Platform Market Trends And Strategies

4. In-vivo Prime Editing Platform Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global In-vivo Prime Editing Platform Growth Analysis And Strategic Analysis Framework

6. In-vivo Prime Editing Platform Market Segmentation

7. In-vivo Prime Editing Platform Market Regional And Country Analysis

8. Asia-Pacific In-vivo Prime Editing Platform Market

9. China In-vivo Prime Editing Platform Market

10. India In-vivo Prime Editing Platform Market

11. Japan In-vivo Prime Editing Platform Market

12. Australia In-vivo Prime Editing Platform Market

13. Indonesia In-vivo Prime Editing Platform Market

14. South Korea In-vivo Prime Editing Platform Market

15. Western Europe In-vivo Prime Editing Platform Market

16. UK In-vivo Prime Editing Platform Market

17. Germany In-vivo Prime Editing Platform Market

18. France In-vivo Prime Editing Platform Market

19. Italy In-vivo Prime Editing Platform Market

20. Spain In-vivo Prime Editing Platform Market

21. Eastern Europe In-vivo Prime Editing Platform Market

22. Russia In-vivo Prime Editing Platform Market

23. North America In-vivo Prime Editing Platform Market

24. USA In-vivo Prime Editing Platform Market

25. Canada In-vivo Prime Editing Platform Market

26. South America In-vivo Prime Editing Platform Market

27. Brazil In-vivo Prime Editing Platform Market

28. Middle East In-vivo Prime Editing Platform Market

29. Africa In-vivo Prime Editing Platform Market

30. In-vivo Prime Editing Platform Market Competitive Landscape And Company Profiles

31. In-vivo Prime Editing Platform Market Other Major And Innovative Companies

32. Global In-vivo Prime Editing Platform Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The In-vivo Prime Editing Platform Market

34. Recent Developments In The In-vivo Prime Editing Platform Market

35. In-vivo Prime Editing Platform Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기